Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Gemfibrozil Study.

V Manninen

    Acta Medica Scandinavica. Supplementum
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Gemfibrozil effectively lowers LDL and VLDL cholesterol while raising HDL cholesterol in patients with dyslipidemia. Clinical trials suggest it may significantly reduce coronary risk, similar to other lipid-lowering therapies.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men.

    Atherosclerosis·2001
    Same author

    Joint effects of C-reactive protein and other risk factors on acute coronary events.

    American heart journal·2001
    Same author

    Infections, inflammation, and the risk of coronary heart disease.

    Circulation·2000
    Same author

    Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction.

    Circulation·1999
    Same author

    Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M.

    Archives of internal medicine·1998
    Same author

    Antibodies to prothrombin crossreact with plasminogen in patients developing myocardial infarction.

    British journal of haematology·1998
    Same journal

    Giving life, giving death: ethical problems of high-technology medicine.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Potential importance of the muscles for the development of insulin resistance in obesity.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Potential role of adipose tissue for the development of insulin resistance in obesity.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Mechanisms associating body fat distribution to glucose intolerance and diabetes mellitus: window with a view.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Physical training and changes in regional adipose tissue distribution.

    Acta medica Scandinavica. Supplementum·1988
    Same journal

    Hormonal abnormalities in obesity.

    Acta medica Scandinavica. Supplementum·1988
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology
    • Lipid Metabolism

    Background:

    • Dyslipidemia is a significant risk factor for cardiovascular disease.
    • Gemfibrozil is a lipid-regulating agent with known effects on lipoprotein levels.
    • Previous studies indicate gemfibrozil's impact on low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and high-density lipoprotein (HDL) cholesterol.

    Purpose of the Study:

    • To evaluate the efficacy of gemfibrozil in managing dyslipidemia.
    • To assess the impact of gemfibrozil on lipid profiles, including LDL, VLDL, and HDL cholesterol.
    • To investigate the potential of gemfibrozil in reducing coronary risk.

    Main Methods:

    • Clinical studies involving dyslipidaemic patients.
    • The Helsinki Heart Study, a large-scale trial comparing gemfibrozil to placebo in 4080 Finnish men (aged 40-55).

    Related Experiment Videos

    Main Results:

    • Gemfibrozil demonstrated significant reductions in LDL (10-20%) and VLDL (30-50%) cholesterol.
    • Gemfibrozil treatment resulted in a notable increase in HDL cholesterol (15-25%).
    • Increases in Apolipoprotein AI (Apo AI), Apolipoprotein AII (Apo AII), kininogen, and prekallikrein were observed.

    Conclusions:

    • Gemfibrozil exhibits a favorable lipid-modifying profile in dyslipidaemic patients.
    • Side-effects associated with gemfibrozil were not a major concern in clinical observations.
    • The Helsinki Heart Study is expected to provide further evidence on gemfibrozil's coronary risk reduction potential, potentially comparable to established therapies like the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT).